Tesofensine

Tesofensine is not a peptide, despite being marketed and sold as one under that label. It is a small-molecule stimulant, chemically related to cocaine, that blocks reuptake of dopamine, noradrenaline and serotonin. It was originally developed for Alzheimer’s and Parkinson’s disease, failed in all four of those trials, and was repurposed for obesity after researchers noticed unexpected weight loss as a side effect. Its pivotal weight-loss trial produced a real effect but also carries a formal Lancet Expression of Concern over under-reported side effects, and the drug is not approved for any use in any country, including Mexico, where a 2023 committee opinion is widely and incorrectly described online as an approval.

Ask about Tesofensine

Research snapshot

CategoryCurrent information
Peptide categoryNot a peptide – small-molecule triple monoamine reuptake inhibitor (substituted phenyltropane)
Primary research interestWeight loss (repurposed from failed Parkinson’s/Alzheimer’s programs)
Highest available evidenceTier 2 – a single published phase 2b human trial (TIPO-1), which carries a formal Lancet Expression of Concern over under-reported adverse events
Human research availableYes, limited – 13 registered trials; the only phase 3 trial (Mexico) remains unpublished
Development statusNo active or recruiting trials; originally NeuroSearch/Boehringer Ingelheim, later Saniona; licensed for Mexico to Productos Medix
Regulatory statusNot approved anywhere. A 2023 Mexican committee opinion is widely misreported as an approval; the sponsor confirmed in November 2024 that approval had not been granted

Technical identity

Technical propertyInformation
Primary nameTesofensine
Alternative namesNS 2330 (code name), Tesofensina, Tesofensinum, tesofensine citrate
Peptide sequenceNot applicable – not a peptide. IUPAC name: (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane
Molecular formulaC17H23Cl2NO (free base); C23H31Cl2NO8 (1:1 citrate salt used in clinical tablets)
Molecular weight328.3 g/mol (free base); 520.4 g/mol (citrate salt)
CAS Registry Number195875-84-4 (free base); 195875-86-6 (citrate)
PubChem CID11370864
Chemical modificationsNot applicable (small molecule, tropane alkaloid family, structurally related to cocaine)
Peptide classNot applicable – small-molecule triple (dopamine/noradrenaline/serotonin) reuptake inhibitor
Primary biological targetDopamine, noradrenaline, and serotonin transporters (reuptake inhibition)
Developer or originatorNeuroSearch (Denmark); passed to Boehringer Ingelheim, then back to NeuroSearch, then Saniona; Mexico licensed to Productos Medix
Development statusNo active or recruiting trials; not approved anywhere

What it is, and what it is not

Tesofensine is not a peptide. It is a small molecule, a substituted phenyltropane, formula C17H23Cl2NO, with no amino acids and no peptide bond. It is in a peptide encyclopedia because people searching peptide terms search for it, and because vendor and clinic pages sell it as one. A live listing titled as tesofensine peptide capsules carries, in its own specification field for amino acid sequence, the words “Not a peptide.”

What it is instead is a stimulant. It blocks reuptake at all three monoamine transporters, at 1.7 nanomolar for noradrenaline, 6.5 for dopamine and 11 for serotonin on the 2025 cryo-EM paper in Nature Communications. That paper states that, like cocaine, tesofensine belongs to the tropane alkaloid family, and notes the 50 fold lower affinity of cocaine for the dopamine transporter than tesofensine. It is a triple reuptake inhibitor with roughly 50 times the dopamine transporter affinity of cocaine, taken as a tablet.

It began at NeuroSearch in Denmark as NS 2330, passed to Boehringer Ingelheim for neurodegenerative disease, back to NeuroSearch for obesity, then to Saniona, and is licensed for Mexico to Productos Medix. All 13 registered human trials used an oral tablet or capsule once daily. Population modelling in 320 patients found half lives of 234 hours for the parent drug and 374 for its active metabolite, so exposure keeps climbing for weeks and persists for weeks after stopping.

It was a brain drug that failed first

Tesofensine was developed for Alzheimer’s and Parkinson’s disease, and that history is missing from almost every page about it. Boehringer Ingelheim ran four 14 week phase 2 trials from 2003 to 2005, two in Parkinson’s disease and two in Alzheimer’s disease, and all four failed. SCEPTRE, in early Parkinson’s disease, found UPDRS differences of minus 0.7 to minus 1.7 across three doses, none significant. ADVANS, in advanced disease, found no clear dose response relationship. The Alzheimer’s trial, NCT00153010, randomised 430 patients across 87 sites, posted no results and was never published: everything the public can verify about its outcome is one clause in a pharmacometrics paper calling it negative.

So the obesity programme exists because of an adverse event. Astrup and colleagues pooled those four trials in 2008, 740 patients against 228 on placebo, none on a weight loss programme. Weight change at 14 weeks was plus 0.5 percent on placebo, then minus 0.5, minus 0.9, minus 1.8 and minus 2.8 percent across 0.125 to 1.0 mg. Their own sentence records the pivot: on the basis of these results, the drug was now being developed for obesity management.

Potential benefits and research applications

Weight loss via appetite suppression

What is being investigated: weight loss through blocking reuptake of dopamine, noradrenaline and serotonin, suppressing appetite as a stimulant would. How the effect might occur: triple monoamine reuptake inhibition altering reward and satiety signaling in the brain. Evidence: the pivotal TIPO-1 trial found roughly 11 to 13 percent absolute weight loss at 24 weeks against 2 percent on diet plus placebo. Strength: has been shown in a randomised controlled human trial. Limitation: that same trial’s published adverse event table was later confirmed by its own authors to under-report side effects, and only one, unpublished phase 3 trial exists.

Originally investigated for Parkinson’s and Alzheimer’s disease (both failed)

What was being investigated: motor symptom improvement in Parkinson’s disease and cognitive benefit in Alzheimer’s disease. How the effect was proposed to occur: dopaminergic and noradrenergic reuptake inhibition supporting motor and cognitive circuits. Evidence: four separate 14-week phase 2 trials, two in each condition, all failed to show a significant benefit. Strength: has not been established for either use; this is the origin story of the obesity indication, discovered as a side effect. Limitation: the 430-patient Alzheimer’s trial was never published, and its outcome survives only as a passing reference calling it negative.

The obesity trials, with the numbers labelled

TrialRouteAmount reportedFrequency reportedReported durationEvidence category
TIPO-1 (pivotal obesity trial, phase 2b)Oral0.25 mg, 0.5 mg, or 1.0 mgOnce daily24 weeksPublished human clinical trial (Lancet) – carries a formal Expression of Concern
Mexican phase 3 (unpublished)Oral0.25 mg or 0.5 mgOnce daily24 weeksSponsor press release only – not registered on ClinicalTrials.gov, never published
Neurodegeneration trials (Parkinson’s/Alzheimer’s, all failed)Oral0.125–1.0 mgOnce daily14 weeksPublished human clinical trials (negative results)
Circulating “research chemical” capsulesOral500 micrograms (0.5 mg) – matches the actual TIPO-1 middle doseOnce dailyNot specifiedCommunity / vendor reported
Marketed by some clinicsInjectionNot specifiedNot specifiedNot specifiedCommunity / vendor reported – no trial has ever used this route

No dose of tesofensine has been established as safe or effective, and no dose is approved in any country. Any chronic daily figure above 1.0 mg, and any injected or sublingual figure, has no trial support whatsoever.

TIPO-1 is the trial every page cites: 203 patients across five Danish centres, 0.25, 0.5 or 1.0 mg or placebo for 24 weeks, in the Lancet in 2008, every arm including placebo on an energy restricted diet. Two sets of its numbers are correct and pages swap them. Placebo subtracted additional weight loss, which is what the abstract reports, was 4.5, 9.2 and 10.6 percent. Absolute mean weight loss was approximately 6.5, 11.2 and 12.6 percent, or 6.7, 11.3 and 12.8 kilograms, against 2.0 percent or 2.2 kilograms on diet plus placebo. Reporting 10.6 percent as absolute understates the drug; 12.8 kilograms as placebo subtracted overstates it. Completion was 161 of 203, 79 percent, so one patient in five did not finish.

Two things commonly cited do not exist. There is no TIPO-3 in any registry, the literature or the sponsor record, the registered obesity trials being TIPO-1, TIPO-2 and TIPO-4, so a page citing TIPO-3 is citing nothing. Nor is there any trial called “Obesity Reduction and Metabolic Improvement.” TIPO-4 is real, an open label extension in 140 TIPO-1 completers over 48 weeks with long term safety as its primary endpoint, and it has no posted results and no publication.

The phase 3 evidence is a press release. One phase 3 trial has ever been run, in Mexico: 372 adults in three arms of 124 on 0.25 mg, 0.5 mg or placebo for 24 weeks. The sponsor’s parent announced that both endpoints were met at p below 0.001, with a ten per cent average weight loss and more than half of patients losing more than ten per cent. It is not registered on ClinicalTrials.gov and has never been published. There are no arm by arm figures, no placebo arm result, no numerical heart rate or blood pressure data and no dropout rates.

The pivotal paper carries an Expression of Concern

No page reviewed for this entry mentions it. The Lancet published an Expression of Concern on TIPO-1 in April 2013, after a Danish Health and Medicines Authority inspection found adverse event recording by the contract research organisation incomplete, because its staff did not consider as noteworthy the recurrence of events. The conclusion, verbatim: the overall side-effect profile that is published in The Lancet is not in accordance with the actual course of the trial. With a limit, also verbatim: data on primary and secondary end-points, and serious adverse events, were reported in accordance with the source data.

The authors’ own published response is worse than the inspection finding. They confirmed that investigators had been wrongly instructed by the monitors not to register headache, migraine, stress, and depression as adverse events if patients reported these conditions before randomisation, found no difference between inspected and uninspected sites, and concluded that listed adverse events from all centres were under-reported in the published paper. Not two bad sites, the whole trial. Two of the four named events are psychiatric, and corrected figures were never published. The efficacy stands. The adverse event table does not.

Safety

The heart rate rise is real, dose dependent, and present at the therapeutic dose in every monotherapy study. In the 968 patient pooled neurodegeneration analysis it ran minus 0.4 beats per minute on placebo, then plus 2.1, plus 4.2, plus 6.0 and plus 6.8 across 0.125 to 1.0 mg, significant from 0.25 mg upward. In TIPO-1 it was plus 7.4 at 0.5 mg. The 2018 Drugs review calls elevations in blood pressure and pulse rate the dose limiting adverse effects.

The blood pressure result needs a subtlety nobody else supplies. No significant rise was detected at 0.25 or 0.5 mg; one was detected at 1.0 mg. But a null result in a trial producing about 11 percent weight loss is not neutral, because losing that much weight should by itself lower blood pressure by several millimetres of mercury. The best framing available, and it comes from a secondary analysis rather than the trial report, is that at 0.5 mg the pressor effect ran roughly 4 to 6 mmHg above the reduction that weight loss alone would have predicted. That blood pressure did not rise is literally true and understates the pharmacology.

The strongest evidence that the signal is serious is the developer’s own behaviour. Saniona stopped developing tesofensine on its own: every trial it ran after 2014 tested Tesomet, 0.5 mg tesofensine fixed with 50 mg of the beta blocker metoprolol. A company does not build a beta blocker into its lead asset over a signal it considers trivial. Cardiovascular outcomes have never been measured in any trial, and the planned two year study was never run. Sibutramine, with a comparable haemodynamic profile, looked acceptable on surrogates for a decade and was withdrawn in 2010 after an outcomes trial.

The common events in TIPO-1 were dry mouth, nausea, constipation, hard stools, diarrhoea and insomnia, with withdrawal for adverse events near 13 percent against 6 on placebo. The best per event figures published are from the 21 patient Tesomet trial, sleep disturbance 50 percent against 13, dry mouth 43 against 0, headache 36 against 0, and those belong to the combination. It also holds the one documented treatment related psychiatric serious adverse event, an exacerbation of pre-existing anxiety. Every obesity trial excluded psychiatric illness, so the measured rates are a floor.

On abuse liability there is one human study. Schoedel and colleagues gave single doses to 52 recreational stimulant users against placebo, d-amphetamine 30 mg as a positive control, and bupropion and atomoxetine; tesofensine did not differ from placebo, and the authors concluded its abuse potential was no greater than bupropion or atomoxetine. One single dose study. There is no repeated dose, withdrawal, tolerance or post marketing data, because the drug has never been marketed. WADA lists it under S6 stimulants, prohibited in competition.

Interactions matter here because of the half lives. Protocols prohibited monoamine oxidase inhibitors for 8 weeks before randomisation and serotonin reuptake inhibitors for 6 weeks. With a 234 hour parent and a 374 hour metabolite, washout runs in weeks in both directions. On CYP3A4, the itraconazole study showed a 9 percent rise in exposure on non-compartmental analysis and a 63 percent rise on semi-mechanistic modelling of the same data.

A 2026 anti-doping paper documents tesofensine marketed online as a dietary supplement for weight management, and dosed six volunteers with 483 micrograms of material bought that way.

Regulatory status, including the Mexico correction

Tesofensine is not approved anywhere the public record confirms. It has never been approved by the FDA, has held investigational status only, has no European authorisation and no ATC code. Mexico is the correction that matters. In February and March 2023 the Comite de Moleculas Nuevas issued a favourable opinion with expert observations, and Mexican headlines used the verbs aprueba and avala, which is where the approval claim comes from. The sponsor’s own release said the favorable opinion does not represent a market authorization. On 6 November 2024 the sponsor stated that Medix has not received approval from the Mexican regulatory agency (Cofepris) for tesofensine. The sponsor said in February 2025 that a revised dossier was expected to be resubmitted that month. No confirmation that it was appears in the public record.

So there is no granted authorisation, no approved brand name, no approved dose and no approved indication text anywhere. Tesomet and Nupenta, named on some pages as approved Mexican products since 2023, could not be verified in any primary or regulatory source. Nothing is in progress either: of 13 registered trial records, 11 are completed and 2 were withdrawn without enrolling anyone.

What the record gets wrong

The route, first. A weight loss clinic markets tesofensine injections. Injection was never used in any of the 13 registered trials, all of which were oral, and the sponsor’s own framing is a tablet requiring no titration. No efficacy or safety trial has ever used an injected dose. The only parenteral human exposure on record is a pharmacokinetic study that infused 0.3 to 1.2 mg intravenously over six hours in 21 healthy subjects to model enterohepatic recirculation, which establishes nothing about a repeated injected dose and was never intended to.

Second, and this one inverts the drug. No significant difference in heart rate or blood pressure is a finding about Tesomet, tesofensine plus 50 milligrams of metoprolol, a beta blocker included to blunt exactly that effect. Quoted as a tesofensine finding, it turns the compound’s most important safety characteristic upside down. Third, the dopamine transporter potency: some secondary tabulations give 65 nanomolar where the primary structural paper gives 6.5, which looks like a decimal error.

The consumer tier is not uniformly bad. Several pages state accurately that it is not FDA approved and investigational only, and one makes the most useful observation anyone has made about its psychiatric profile: trials excluded active psychiatric disease, so the real world rate may be higher.

Every page saying tesofensine is approved in Mexico is repeating a newspaper headline about an advisory opinion that the sponsor itself said does not represent a market authorisation, and that the sponsor confirmed two years later had not produced an approval. There is no approved dose of tesofensine in any country. The only doses that exist are the ones trials administered, and the pivotal trial’s own adverse event table is an undercount its authors have admitted in print.

Frequently asked questions

What is tesofensine?

A small-molecule triple monoamine reuptake inhibitor, not a peptide, originally developed for Parkinson’s and Alzheimer’s disease and repurposed for obesity after it caused unexpected weight loss in those failed trials.

How does it work?

It blocks reuptake of dopamine, noradrenaline and serotonin at once, chemically related to cocaine’s mechanism, with roughly 50 times cocaine’s affinity for the dopamine transporter. That suppresses appetite as a side effect of its stimulant action.

What dosage has been studied?

Oral doses of 0.125 to 1.0 mg once daily across 13 registered trials, all of them tablets or capsules. The pivotal obesity trial used 0.25, 0.5 and 1.0 mg once daily for 24 weeks.

What dosage commonly circulates online?

500 micrograms (0.5 mg) once daily by mouth is the dominant figure, which happens to match the actual middle dose of the pivotal trial. Injectable versions are also marketed by some clinics despite no trial ever using that route.

Has it been studied in humans?

Yes, in 13 registered trials across Parkinson’s disease, Alzheimer’s disease and obesity, plus one unpublished phase 3 trial in Mexico. It has never completed a cardiovascular outcomes trial.

Is it approved anywhere?

No. A 2023 Mexican regulatory committee issued a favorable opinion that Mexican media reported as an approval, but the sponsor itself said that opinion does not represent market authorization, and confirmed in November 2024 that approval had still not been granted.

What side effects have been reported?

A dose-dependent heart rate increase present at every studied dose, dry mouth, nausea, constipation and insomnia. The pivotal trial’s published side-effect table was formally found by regulators to under-report adverse events, an admission the study’s own authors later confirmed in print.

Why does the Lancet Expression of Concern matter?

It means the safety data underlying the drug’s best-known weight-loss trial cannot be fully trusted as published. A regulatory inspection found the side-effect profile did not match what actually happened during the trial, and the study authors confirmed under-reporting at every site, not just one problem location.

What remains unknown?

Cardiovascular safety over any meaningful duration, the true adverse event rate given the confirmed under-reporting, what the unpublished 430-patient Alzheimer’s trial and the 372-patient Mexican phase 3 trial actually found, and whether development will continue given no active trials are currently recruiting.

Bottom line

Tesofensine produced genuine, clinically meaningful weight loss in its pivotal trial, but it is not a peptide, it was developed for entirely different conditions before failing in both, and its central safety dataset has been formally flagged by regulators and its own authors for under-reporting adverse events. It has never been approved anywhere, despite persistent claims that Mexico approved it, and no cardiovascular outcomes data exist for a stimulant that measurably raises heart rate at its studied dose. The version circulating online at 500 micrograms happens to match a real trial dose, which makes it more pharmacologically active, not safer.

What circulates E5

Figures reported online. Not dosing, not verified, not endorsed.
Reported useRouteAmount reportedFrequencyReported length
Weight loss, sold as a research chemicalOral capsule500 micrograms, that is 0.5 mgOnce dailyNot specified
Weight loss, marketed by a clinicInjectionNot specifiedNot specifiedNot specified
Sold as a dietary supplementOral~483 mcg (per one tested supplement sample)Not specifiedNot specified

Tesofensine circulates as oral capsules, commonly labelled 500 micrograms, under research use framing, and also as an ingredient in products sold online as dietary supplements. The dominant figure is 500 micrograms once daily.

That figure is unusual for this site, because it is not an inflation. It is exactly 0.5 mg, the middle arm of the pivotal trial and the dose the sponsor calls its expected recommended dose. A capsule bought online therefore contains a fully pharmacological dose of an unapproved triple reuptake inhibitor with a 10 day half life, sold in at least one case under a disclaimer stating that introduction into humans or animals is forbidden.

What the circulating material omits is everything that makes 0.5 mg a considered number rather than a convenient one. It omits the 7.4 beat per minute heart rate rise recorded at that exact dose. It omits that one patient in five did not complete the 24 week trial. It omits that the trial's published adverse event table is an undercount by its own authors' admission. It omits that no cardiovascular outcome has ever been measured on this drug, and that no regulator anywhere has approved any dose of it.

The dietary-supplement figure, when tested, has come out around 483 micrograms of tesofensine in a sample of the actual material, close to the 500-microgram capsule figure.

One circulating route has no support at all. Injected tesofensine is marketed by at least one clinic, and injection was never used in any of the 13 registered human trials. There is no dose, no pharmacokinetic profile and no safety data for that route.

Circulating material gives no cycle length, no total duration, no stopping rule and no monitoring. Three absences matter more here than usual. There is no instruction to check a pulse, on a drug whose reviews call heart rate its dose limiting toxicity. There is no warning about antidepressants, when trial protocols banned monoamine oxidase inhibitors for 8 weeks and serotonin reuptake inhibitors for 6. And there is no mention of accumulation, when the parent drug and its active metabolite have half lives of about 10 and 15 days, so exposure keeps climbing for weeks after a stable daily amount is started and keeps going for weeks after it stops.

Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.

Sources

  1. Lehr T, Staab A, Tillmann C, Trommeshauser D, Schaefer HG, Kloft C. A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam. Clin Pharmacokinet. 2009. Human, n=21 healthy subjects in a double blind, randomised, placebo controlled single rising dose study. Source for tesofensine 0.3, 0.6, 0.9 and 1.2 mg given as single 6 hour intravenous infusions, and for the multiple peak plasma profile that the model attributes to enterohepatic recirculation through a gallbladder compartment. PMID 19705923
  2. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008. Human phase 2b, n=203, the pivotal trial. Carries an Expression of Concern and an authors' admission of adverse event under reporting. PMID 18950853
  3. Expression of concern: effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients. Lancet. 2013. Following a November 2011 Danish Health and Medicines Authority inspection. States that the published side-effect profile is not in accordance with the actual course of the trial, while confirming that endpoints and serious adverse events matched source data. PMID 23561987
  4. Astrup A, et al. Under-reporting of adverse effects of tesofensine. Lancet. 2013. The authors' own reanalysis, human. Investigators were wrongly instructed not to record headache, migraine, stress and depression as adverse events; inspected and uninspected sites did not differ, indicating under reporting at all centres. PMID 23849924
  5. Astrup A, Meier DH, Mikkelsen BO, Villumsen JS, Larsen TM. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Obesity. 2008. Human meta-analysis of four 14 week RCTs, 740 versus 228. Source of the dose dependent weight and heart rate figures and of the documented switch to obesity as an indication. PMID 18356831
  6. Hauser RA, Salin L, Juhel N, Konyago VL. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 in early Parkinson's disease. Mov Disord. 2007. Human phase 2, n=261, negative on UPDRS at all three doses. PMID 17149725
  7. Rascol O, et al. Tesofensine in patients with advanced Parkinson disease and motor fluctuations: the ADVANS study. Arch Neurol. 2008. Human phase 2, n=254, five arms, no clear dose response; gastrointestinal and neuropsychiatric events more frequent than placebo at higher doses. PMID 18474731
  8. Boehringer Ingelheim. Phase 2 trial of three doses of NS 2330 in mild to moderate Alzheimer's type dementia, n=430 across 87 sites, completed March 2005. No results posted and no primary publication. Source of the protocol prohibitions on monoamine oxidase inhibitors, serotonin reuptake inhibitors and CYP3A4 inhibitors. NCT00153010
  9. Lehr T, Staab A, Trommeshauser D, Schaefer HG, Kloft C. Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine. AAPS J. 2010. Human modelling. The only public source describing the 430 patient phase 2b trial, which it calls negative. PMID 20077053
  10. Sjodin A, et al. The effect of tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes. 2010. Human RCT, n=32 men, 2.0 mg then 1.0 mg over 14 days with habitual intake maintained; 1.8 kg above placebo, night energy expenditure plus 4.6 percent, fat oxidation plus 18 g. PMID 20479765
  11. NeuroSearch A/S. Evaluation of long term safety of tesofensine in patients with obesity, n=140 TIPO-1 completers, 48 weeks, primary endpoint long term safety including ophthalmoscopy and ECG. No results posted and no publication located. NCT00481104
  12. Huynh K, et al. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. Eur J Endocrinol. 2022. Human phase 2, n=21, 0.5 mg tesofensine with 50 mg metoprolol. The only published randomised Tesomet trial. Its finding of no heart rate or blood pressure difference is attributable to the metoprolol and is not a tesofensine finding. PMID 35294397
  13. Schoedel KA, Meier D, Chakraborty B, Manniche PM, Sellers EM. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clin Pharmacol Ther. 2010. Human, n=52, single dose crossover against placebo, d-amphetamine 30 mg, bupropion and atomoxetine. The only human abuse liability data that exists. PMID 20520602
  14. Lehr T, et al. Population pharmacokinetic modelling of NS2330 and its major metabolite in patients with Alzheimer's disease. Br J Clin Pharmacol. 2007. Human, n=320. Half lives of 234 hours for the parent and 374 hours for the metabolite M1; women with reduced creatinine clearance had 62 percent higher exposure than men without renal impairment. PMID 17324246
  15. Lehr T, et al. Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole. Clin Pharmacokinet. 2010. Human, n=28. Non-compartmental analysis showed a 9 percent exposure increase; semi-mechanistic modelling showed a 38 percent clearance reduction and a 63 percent exposure increase. PMID 20000889
  16. Krug O, Thomas A, Thevis M. Investigations into the metabolism and elimination of tesofensine in human urine. Drug Test Anal. 2026. Human excretion study, n=6 dosed with 483 micrograms obtained as a dietary supplement. Records WADA S6 stimulant status, prohibited in competition, and that the compound is marketed online as a supplement. PMID 42320973
  17. Nat Commun. 2025. Preclinical cryo-EM structures of tesofensine bound to the dopamine, noradrenaline and serotonin transporters. The authoritative source for transporter potencies of 6.5, 1.7 and 11 nanomolar, for the tropane alkaloid classification, and for the 50 fold lower affinity of cocaine for the dopamine transporter than tesofensine. PMID 41392177
  18. Coulter AA, Rebello CJ, Greenway FL. Centrally acting agents for obesity: past, present, and future. Drugs. 2018. Human and preclinical review. States the half life as over 8 days, records the 1.0 mg blood pressure rise and the headache and mood findings, and calls elevations in blood pressure and pulse rate the dose limiting adverse effects. PMID 30014268
  19. Saniona AB. Mexican application for tesofensine not yet approved, 6 November 2024. States that Medix has not received approval from the Mexican regulatory agency, Cofepris, for tesofensine. The same company's release of 25 February 2023 states that the new molecules committee opinion does not represent a market authorization. Cited for regulatory facts only, not as evidence of efficacy or safety. Saniona AB company announcement, 6 November 2024

Live registry status

These are the registered trials this page cites, pulled from ClinicalTrials.gov and refreshed automatically. Status and dates are what the registry currently shows. Listing a trial here does not mean it produced a positive result.

Open these in the trial tracker

Research area: Metabolic and incretin.

Share thisFacebookXEmail